Latest Consumer Health Products News

Bioxyne Limited has reported a remarkable half-year performance, with revenues soaring 149% to $31.3 million and net profit more than doubling to $7.3 million, driven by strong demand for medicinal cannabis, MDMA, and psilocybin products and expanding international operations.

Starpharma reports a $1.37 million profit for H1 FY26, driven by a major upfront payment from Genentech and progress in its radiopharmaceutical pipeline. The biotech also expands its consumer health footprint amid growing partnerships.

Aumake Limited has secured a four-year exclusive global distribution agreement with EZZ Life Sciences, targeting $10 million in sales and expanding its footprint in high-margin nutraceuticals.

Bioxyne Limited has delivered a record-breaking second quarter in FY2026, posting $17.2 million in revenue and expanding its footprint into key international markets. The company’s growth is underpinned by new contracts, innovative psychedelics products, and strategic government funding.

Wellnex Life reports a significant turnaround with a 31.5% revenue increase and near break-even operating cash flow in the December quarter, driven by strategic brand consolidation and cost discipline.

Wellnex Life reports encouraging early results from its turnaround strategy, posting a modest EBITDA profit and robust sales growth for its Pain Away brand.

Hydralyte USA reported a 6% year-on-year sales increase in Q3 FY25 alongside a significant 42% reduction in operating cash burn, driven by a streamlined US-focused model and new product launches in brain and gut health.

Hydralyte USA reports an 11% sales increase in Q3 2025, driven by strong summer demand and the launch of its innovative Hydralyte Plus Brain Support product featuring nootropics.

Wellnex Life Limited announces key board and management changes following its successful AIM Market dual listing, including the resignation of its Non-Executive Chairman and appointment of a joint CEO to drive growth.

Wellnex Life has secured Therapeutic Goods Administration approval for its Liquid Paracetamol plus Caffeine Soft Gel, marking its fourth market authorisation and opening new revenue avenues.